A study introduces a scalable 2D human neuron platform to probe how brain-like rhythms emerge and how specific drugs reshape them, aiding epilepsy and autism research.

A study published in Cell Stem Cell on February 5, 2026, traces a direct signaling chain from sleep-deprived brains to ...

The CAR T-cell therapy market is ripe for growth with over 250 companies and 500 drugs in development globally. Key opportunities lie in targeting hematologic malignancies and overcoming challenges in ...

Satellos Bioscience Inc. (NASDAQ: MSLE, TSX: MSCL) (“Satellos” or the “Company”), a clinical-stage biotechnology company developing life-improving medicines to treat degenerative muscle diseases, ...

The London Company Mid Cap portfolio returned 3.2% in Q4 2025, outperforming its benchmark. See which stocks drove these gains and new portfolio additions.

New research shows that physical pressure from brain tumors or injuries triggers a "self-destruction" program in neurons, leading to irreversible brain damage.

By David Bautz, PhD NASDAQ:ESLA Business Update On February 9, 2026, Estrella Immunopharma, Inc. (NASDAQ:ESLA) announced that results from the Phase 1 Trial of CD19-ARTEMIS® T cells (EB103) in ...

The discovery that tissues use electricity to expel unhealthy cells is part of a surge of renewed interest in the currents flowing through our bodies. We’re used to thinking of the brain as an ...

A first-of-its-kind trial is testing adult stem cell transplants for advanced dry macular degeneration. Early results show the treatment is safe and can significantly improve vision, even in severely ...

Johnson & Johnson is paying $3.05 billion to acquire Halda Therapeutics, obtaining a novel cell death platform while strengthening its prostate cancer franchise built on Erleada. At the center of the ...